Connect your AI

Pulmonx Corporation LUNG Restricted Cash

Restricted Cash at other companies

Theravance BiopharmaTBPH

$836K0.0%

LQD

Liquidia CorporationLQDA

$3.5M—

MannkindMNKD

$747K+1.1%

InogenINGN

$1.3M-64.5%

Intuitive SurgicalISRG

——

Other financials

Income statement

Revenue$20.6M-8.7%

Gross profit$16.0M-1.8%

Operating income-$13.0M+11.0%

Net income-$13.7M+5.5%

EPS (diluted)-$0.33+8.3%

Balance sheet

Cash & equivalents$61.0M-2.4%

Total debt$56.3M-1.2%

Total equity$45.8M-41.1%

Total assets$120.0M-20.4%

Cash flow

Operating cash flow-$10.1M+23.6%

CapEx$9.0K-97.0%

Free cash flow-$10.1M+25.3%

Valuation

Market cap$54.91M-43.7%

Enterprise value$50.17M-39.2%

P/S0.6×-0.5×

Profitability

Gross margin75.5%+2.0pp

Operating margin-58.8%-5.8pp

Net margin-60.1%-4.4pp

FCF margin-33.2%-4.4pp

Returns & leverage

Return on equity-86.2%+62.6pp

Debt / equity1.2×+0.5×

Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCash.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Pulmonx Corporation's restricted cash?: Pulmonx Corporation (LUNG) reported restricted cash of $257K in Q1 2026.
How has Pulmonx Corporation's restricted cash changed year-over-year?: Pulmonx Corporation's restricted cash decreased by 0.0% year-over-year, from $257K to $257K.
What is the long-term trend for Pulmonx Corporation's restricted cash?: Over 5 years (2020 to 2025), Pulmonx Corporation's restricted cash has grown at a 2.2% compound annual growth rate (CAGR), from $231K to $258K.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.